Scancell HoldingsSCNLF 20 EBITDA Margin % is 0.00% as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Scancell Holdings ranks worse than 54.87% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Scancell Holdings's EBITDA for the
six
months ended in Oct. 2025 was $-7.28 Mil. Scancell Holdings's Revenue for the
six
months ended in Oct. 2025 was $0.00 Mil. Therefore, Scancell Holdings's EBITDA margin for the quarter that ended in Oct. 2025 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Scancell Holdings EBITDA Margin % Related Terms
Scancell Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNLF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Scancell Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (SCNLF) has a EBITDA Margin % of 0.00% as of Oct. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #518 out of 944 companies in the Biotechnology industry, placing it in the top 54.9%.
Is Scancell Holdings' EBITDA Margin % too high?
Scancell Holdings' current EBITDA Margin % is 0.00%. Based on the distribution chart, Scancell Holdings ranks #518 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #518 out of 944 companies for EBITDA Margin %. This places Scancell Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current EBITDA Margin % is 0.00% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score
Get the complete analysis for SCNLF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
